Abstract:Objective: This article investigated the clinical characteristics and distribution of drug resistance mutation sites in HBV RT region of hepatitis B infected patients. Methods: Retrospective analysis was made on 1 948 patients with HBV infection, who had been tested for NAs resistance mutation and had a medical history of NAs in the Laboratory Department of the Fifth Medical Center of the PLA General Hospital from January 2020 to December 2021. Basic clinical information and drug resistance related mutation information were recorded. Meanwhile, the serological index data of hepatitis B were collected. Drug resistance gene mutant group and non-mutated group were grouped according to whether the drug resistance genes had a mutation in HBV RT region, and the clinical characteristics and genotype distribution of the two groups were statistically analyzed. The pattern of drug resistance gene mutation, number of mutation sites, drug resistance type and mutation of NAs resistance-related sites were analyzed in 917 patients with drug resistance gene mutation in HBV RT region. χ2 Inspection was used for counting data. Meanwhile, two independent samples t-test and Wilcoxon rank sum test were used for measurement data. Results: Among the 1 948 patients with chronic HBV infection, 917 patients had drug resistance gene mutation in RT region (47.07%). The proportion of patients with acute hepatitis B and CHB in HBV RT resistance gene mutant group was lower than that in the non-mutated group, while the proportion of patients with HBV-related cirrhosis was higher than that in the non-mutated group, these differences were statistically significant. Compared with the non-mutated group in HBV RT region, the age, the positive rates of HBeAg and HBV DNA, and HBV DNA load of these patients were increased in drug resistance gene mutant group, these differences were statistically significant. Genotypes of patients in both groups were dominated by C, followed by B and D. The proportion of patients with genotype C in HBV RT drug resistance gene mutant group was higher than that of non-mutated group, the difference was statistically significant. There were 53 gene mutation patterns in 917 patients with drug resistance gene mutation in HBV RT region, and the main pattern was rtL180M+rtM204V+rtS202G (9.70%). The mutation sites were dominated by 3 (20.74%). There were 5 types of drug resistance, LAM+Ldt (21.25%) was the most. Among the 18 sites that were clearly associated with LAM, ADV, ETV and Ldt resistance in the HBV RT region, 14 sites were mutated, and the most common mutation sites were rtL180M, rtM204V, rtM204 and rtS202G. what's more, the proportion of patients with NAs drug resistance was LAM>Ldt>ETV>ADV. Conclusion: In order to prevent adverse consequences of this study such as disease recurrence or disease progression caused by HBV drug resistance, HBV infected patients, who have long-term use of NAs antiviral therapy, should monitor the level of HBV DNA and drug resistance genes in HBV RT region in order to optimize the treatment plan in time or guide individualized treatment.

Accumulation of mutations in reverse transcriptase of hepatitis B virus is associated with liver disease severity in treatment-naïve Chinese patients with chronic hepatitis B.

Correlation of the Occurrence of YMDD Mutations with HBV Genotypes, HBV-DNA Levels, and HBeAg Status in Chinese Patients with Chronic Hepatitis B During Lamivudine Treatment

The Central Nervous System is a Potential Reservoir and Possible Origin of Drug Resistance in Hepatitis B Infection

Pre-Existing Mutations in Reverse Transcriptase of Hepatitis B Virus in Treatment-Naive Chinese Patients with Chronic Hepatitis B

Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.

Prevalence And Significance Of Hepatitis B Reverse Transcriptase Mutants In Different Disease Stages Of Untreated Patients

Pre-core/basal-core Promoter and Reverse Transcriptase Mutations in Chronic HBV Infected-Patients.

Gene Heterogeneity of Hepatitis B Virus Isolates from Patients with Severe Hepatitis B.

Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.

Novel Natural Mutations in the Hepatitis B Virus Reverse Transcriptase Domain Associated with Hepatocellular Carcinoma.

Profile of Hbv Antiviral Resistance Mutations with Distinct Evolutionary Pathways Against Nucleoside/Nucleotide Analogue Treatment among Chinese Chronic Hepatitis B Patients

Discrepancy of Potential Antiviral Resistance Mutation Profiles Within the HBV Reverse Transcriptase Between Nucleos(t)ide Analogue‐untreated and ‐treated Patients with Chronic Hepatitis B in a Hospital in China

Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure

Prevalence of rt229 polymerase mutations of hepatitis B virus and its influence on the viral replication

Hepatitis B Virus Mutations Associated with in Situ Expression of Hepatitis B Core Antigen, Viral Load and Prognosis in Chronic Hepatitis B Patients

Mutations in Precore and Core Promoter Region of HBV in Patients with Hepatic Failure.

[Analysis of characteristics of drug resistance gene mutation in HBV RT region of hepatitis B infected patients]

The characterization and clinical significance of quasispecies in the reverse transcriptase region of hepatitis B virus in hepatitis B virus infected patients with different disease stages

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection

Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients

Higher Detection Rates of Amino Acid Substitutions in HBV Reverse Transcriptase/surface Protein Overlapping Sequence is Correlated with Lower Serum HBV DNA and HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Subgenotype B2